-
2024-516605-23-00
5
2025-05-12
relapsed/refractory nodal T cell lymphoma with T follicular helper (TF
-
2024-515593-27-00
5
2025-05-08
relapsed or refractory mantle cell lymphoma (R/R MCL)
-
2024-515793-27-01
5
2025-04-30
HIV
-
2023-506601-19-00
6
2025-04-15
transplantation
-
2023-505789-27-00
4
2025-04-14
Relapsed or Refractory Non-Hodgkin Lymphoma
-
2024-516791-15-00
4
2025-04-08
Relapsed/Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)
-
2024-512633-32-00
4
2025-04-07
Crohn's disease
-
2023-504550-35-00
5
2025-04-03
Atypical Hemolytic Uremic Syndrome (aHUS)
-
2022-501489-24-00
5
2025-03-28
First-line treatment of adult subjects with high-risk large B-cell lym
-
2023-504086-23-00
5
2025-03-27
Subjects with PBC with a non-optimal response to UDCA.
-
2024-514804-14-00
6
2025-03-26
Liver transplantation
-
2023-507937-14-00
7
2025-03-25
Metastatic Solid Tumor
-
2024-514261-19-00
9
2025-03-24
Locally advanced, unresectable or metastatic cholangiocarcinoma with a
-
2023-510079-74-00
5
2025-03-06
meniscal pain of degenerative origin
-
2024-515034-33-00
9
2025-03-05
Mantle Cell Lymphoma
-
2024-517419-62-00
4
2025-02-28
HER2 mutation
-
2024-515020-36-00
9
2025-02-24
Advanced Solid tumour
-
2024-516044-25-00
10
2025-02-13
Migraines with aura
-
2024-516306-28-00
10
2025-02-12
Autism with Spectrum Disorders and Moderate to Severe Intellectual Dis
-
2023-506706-40-00
10
2025-02-11
Mantle-Cell Lymphoma
-
2023-508798-94-00
5
2025-02-11
Heart failure
-
2023-509632-26-00
9
2025-02-11
Recurrent or Metastatic Solid Tumors (endometrial cancer (EC); head an
-
2023-509806-31-00
4
2025-02-11
Non-Small Cell Lung Cancer
-
2024-513475-41-00
5
2025-02-03
Multiple Sclerosis